ACR Convergence 2026

November 6–11, 2026
Orlando, US



PsOPsAHub

TOP ABSTRACTS

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2026, November 6–11, 2026, Orlando, US, the PsOPsA Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in psoriatic disease.

Intended for healthcare professionals. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

ACR 2026: Top abstracts in psoriatic disease

November 6–11, 2026

Oral presentations: Sunday, November 8			
Abstract	**Title**	**Presenter**	**Time (EST)**
0867 View	Weight loss following GLP-1 receptor agonist initiation is associated with improved patient reported outcomes in rheumatoid arthritis and psoriatic arthritis	Jeffrey Curtis	10:15–10:30
0879 View	Identification of protein signatures tracking changes of disease activity of PsA disease domains and improvement with deucravacitinib treatment in phase 3 clinical studies	Vinod Chandran	08:45–09:00
0881 View	Difficult-to-treat psoriasis identifies patients at increased risk of incident psoriatic arthritis: A population-based time-varying cohort study	Paula David	09:15–09:30

Oral presentations: Tuesday, November 10			
Abstract	**Title**	**Presenter**	**Time (EST)**
2804 View	Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 24-Week results from a head-to-head, multicenter, randomized, phase 3b study	Joseph Merola	10:15–10:30

Oral presentations: Wednesday, November 11			
Abstract	**Title**	**Presenter**	**Time (EST)**
2942 View	Ixekizumab plus tirzepatide demonstrated greater disease control at 52 weeks versus ixekizumab alone with incremental improvement from Week 36 in adults with psoriatic arthritis and overweight or obesity: Results from a randomised clinical trial	Joseph Merola	09:45–10:00
2943 View	Biomarker-driven insights from the phase 2a AFFINITY study evaluating guselkumab + golimumab combination therapy versus guselkumab monotherapy in psoriatic arthritis	Iain McInnes	10:00–10:15

Posters			
Abstract	**Title**	**Presenter**	**Date and time (EST)**
0344 View	A phase 4, prospective, open-label study to assess the effectiveness of adding tirzepatide after initiation of ixekizumab in adults with psoriatic arthritis and overweight or obesity	Catherine Bakewell	Sunday, November 8, 10:30–12:30
0348 View	Baseline characteristics and 12-month effectiveness of guselkumab and IL-17 inhibitors among participants with oligoarticular psoriatic arthritis in the global PsABIOnd study	Frank Behrens	Sunday, November 8, 10:30–12:30
0358 View	Effectiveness of guselkumab vs golimumab in participants with active psoriatic arthritis and inadequate response to one prior tumor necrosis factor inhibitor: Interim results at 6 months in a phase 3b, randomized, open-label, pragmatic trial	Alexis Ogdie	Sunday, November 8, 10:30–12:30
0359 View	Efficacy and safety of tildrakizumab in anti-TNF-naïve patients with active psoriatic arthritis: Week 52 results from a phase 3, randomized, double-blind, placebo-controlled trial	Philip Mease	Sunday, November 8, 10:30–12:30
0368 View	Persistence, effectiveness, safety, and patient reported impact of guselkumab and IL-17 inhibitors in psoriatic arthritis: Full population results of the PsABIOnd global observational study over 12 months	Laure Gossec	Sunday, November 8, 10:30–12:30
0373 View	Treatment with glucagon-like peptide-1 receptor agonists is associated with lower disease activity and pain in psoriatic arthritis independent of weight change	Pankti Mehta	Sunday, November 8, 10:30–12:30
1306 View	Bimekizumab demonstrated maintenance of clinical efficacy responses to 3 years in patients with active psoriatic arthritis from two phase 3 studies	Jessica Walsh	Monday, November 9, 10:30–12:30
1310 View	Cumulative days of musculoskeletal improvement in bio-naïve patients with PsA with or without metabolic syndrome and obesity receiving risankizumab through week 244: Integrated results from the KEEPsAKE clinical trials	Saakshi Khattri	Monday, November 9, 10:30–12:30
1312 View	Efficacy and safety of guselkumab in participants with active psoriatic arthritis and inadequate response/ intolerance to one prior tumor necrosis factor inhibitor through 1 year of the SOLSTICE study	Bea Rivard	Monday, November 9, 10:30–12:30
1313 View	Efficacy of izokibep, a novel IL-17A inhibitor, in patients with active psoriatic arthritis: Composite measures of disease activity and patient-reported outcomes from a randomized, double-blind, placebo-controlled, multicenter, phase 2b/3 study	Philip Mease	Monday, November 9, 10:30–12:30
1314 View	Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, phase 3 ONWARD1 and 2 studies	Elisa Muscianisi	Monday, November 9, 10:30–12:30

1326 View	Real-world effectiveness of risankizumab in patients with psoriatic arthritis: 6-month interim results from the observational PErsistence with RISankizumab (PERIS) study	Carlo Selmi	Monday, November 9, 10:30–12:30
2293 View	Efficacy of apremilast in patients with early psoriatic arthritis: A post hoc pooled analysis of seven clinical trials	Philip Mease	Tuesday, November 10, 10:30–12:30
2295 View	Guselkumab efficacy on improvements in American College of Rheumatology response components and association with structural damage progression in participants with active and erosive psoriatic arthritis: Results from a phase 3b, randomized double-blind, placebo-controlled study	Proton Rahman	Tuesday, November 10, 10:30–12:30
2297 View	Ixekizumab and concomitant tirzepatide achieved early disease control in adults with psoriatic arthritis and obesity/overweight: phase 3b TOGETHER-PsA trial	Mohamed Sheesh	Tuesday, November 10, 10:30–12:30
2313 View	Tildrakizumab for the treatment of prior anti-tumor necrosis factor-experienced or -naïve participants with active psoriatic arthritis: Pooled Week 24 results of two Phase 3, randomized, double-blind, placebo-controlled studies, INSPIRE 1 and INSPIRE 2	Philip Mease	Tuesday, November 10, 10:30–12:30
LB12 View	Icotrokinra, an IL-23 receptor targeted oral peptide, in biologic-naïve participants with active psoriatic arthritis: Results through Week 24 of a phase 3, randomized, double-blind, placebo-controlled study	Joseph F. Merola	Tuesday, November 10, 10:30–12:30

#ACR26

Follow us on X to keep up to date with the latest from the congress

@Psoriasis_Hub

PsOPsAHub

Brought to you by

SES

Intended for healthcare professionals. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.